RecruitingISRCTN59554792
Xanomeline-trospium versus standard antipsychotics for cognition in early psychosis
About this title
The efficacy of xanomeline-trospium in treating cognitive impairment in psychosis: a randomised, double-blind active-controlled clinical trial
Read the official source — ISRCTN59554792Research studyAges 18–55United KingdomSchizophrenia
Understand this study
Who could participate?
Listed age limits: 18 years to 55 years.
- Listed locations
- United Kingdom
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- University of Oxford
- Sponsor type
- University
- Study type
- Other
- Intervention type
- Other / unclear
- Locations
- United Kingdom
- Age range
- From 18 Years to 55 Years
- Official registry ID
- ISRCTN59554792
- Official title
Show the full official title
The efficacy of xanomeline-trospium in treating cognitive impairment in patients with a psychotic disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
United Kingdom
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Oxford, a university.
Who can participate?
Listed age limits: 18 years to 55 years.
Is this study still recruiting?
The registry lists this study as recruiting.
